For the first time, tagatose has been certified as Plant-Based and Vegetarian. Tagatose is an ultra-low glycemic index sugar substitute found in tiny quantities in plants such as apples, pineapples, and the sap of a tree related to the cocoa tree. But because tagatose is found in nature is such small amounts, for commercial purposes it must be made from other food materials. In the case of other companies, tagatose is made from dairy-derived lactose and, therefore, is not plant-based. That other process involves multiple separation, conversion and purification steps that result in a high-cost product that suffers from scalability challenges. In contrast, Bonumose’s unique method enzymatically converts plant starch (e.g., potato, cassava, corn, etc.) to tagatose in a high-yield, high-purity process. Bonumose’s tagatose is made from a globally abundant food commodity (starch), using the same kind of equipment that is used to make common, inexpensive sweeteners. This results in cost-savings for food companies and their consumers. Based on application materials prepared by Bonumose’s Director, Regulatory & Nutrition, Dr. Karen Weikel, Bonumose’s tagatose achieved certification under FoodChain ID’s “Vegetarian and Plant-Based Product” Standard. Dr. Weikel has been responsible for many other certifications for Bonumose’s tagatose, such as Non-GMO (aka “butterfly stamp”), Ketogenic, Kosher (Orthodox Union), and Halal (Ifanca), and played an important role in Bonumose’s Safe Quality Foods certification. Tagatose does not increase blood glucose or insulin. Tagatose is beneficial for dental/oral health. It has 62% fewer calories than sugar. Tagatose acts similarly to dietary fiber in the gut where beneficial bacteria use it to produce healthy short-chain fatty acids. Meanwhile, tagatose retains a taste and flavor nearly indistinguishable from sugar (sucrose), with 92% of the sweetness, and a “cookability” that more closely resembles sugar than other sugar substitutes do. Bonumose’s first tagatose production facility is located near Charlottesville, Virginia. Tagatose is available for bulk purchase through ASR Group. |
|
|
News
Recent News
11/21/2024
TearSolutions, Inc. Secures $3M Series B Funding
TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of ocular surface related diseases, today announced the successful closure of a $3M Series B round designed to accelerate its development programs for rare corneal diseases at both pre-clinical and clinical stages. “This round of financing is significant for several reasons, …
11/21/2024
ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of the Board
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced the appointment of Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of its Board of Directors, effective immediately. Edward A. “Buzz” Heidt Jr., who has served …
11/13/2024
VIPC Awards Regional Innovation Ecosystem Grant to Verge to Accelerate the Growing Innovation Economy Throughout Roanoke and The New River Valley
The Virginia Innovation Partnership Corporation (VIPC) announced that Roanoke and Blacksburg, Virginia-based Verge has been awarded a Regional Innovation Fund (RIF) grant for $200,000. Verge is the region’s front door for innovators, founders, and funders to work together and to provide a growing roster of companies – both startups and established – with resources to …